In 2022, based on the results of the DESTINY-Breast03 trial [63], T-DXd was also approved as a second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. Here, ERBB2 is linked to breast carcinoma.